[go: up one dir, main page]

MA27843A1 - Preparation et utilisation de derives d'aryl alkyl acide pour le traitement de l'obesite - Google Patents

Preparation et utilisation de derives d'aryl alkyl acide pour le traitement de l'obesite

Info

Publication number
MA27843A1
MA27843A1 MA28625A MA28625A MA27843A1 MA 27843 A1 MA27843 A1 MA 27843A1 MA 28625 A MA28625 A MA 28625A MA 28625 A MA28625 A MA 28625A MA 27843 A1 MA27843 A1 MA 27843A1
Authority
MA
Morocco
Prior art keywords
ingap104
peptide
obesity
preparation
treatment
Prior art date
Application number
MA28625A
Other languages
English (en)
Inventor
Roger Smith
Ann-Marie Campbell
Philip Coish
Miao Dai
Susan Jenkins
Derek Lowe
Stephen O'connor
Ning Su
Gan Wang
Mingbao Zhang
Lei Zhu
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of MA27843A1 publication Critical patent/MA27843A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/60—Naphthoxazoles; Hydrogenated naphthoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/58—Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

DOSAGE D'ANTICORPS ANTI-INGAP L'invention concerne un test en phase solide utilisé afin de détecter des anticorps contre le peptide INGAP104-118, un peptide de 15 acides aminés qui constitue la partie biologiquement active de la protéine associée à la néogenèse des îlots de Langerhans (INGAP). L'isotype des anticorps dirigés contre le peptide INGAP104-118 peut être déterminé. On peut aussi utiliser un kit de détection des anticorps anti-INGAP104-118. Il est ainsi possible de suivre la production d'autoanticorps endogènes ou d'anticorps lors d'un traitement thérapeutique d'un mammifère avec le peptide INGAP104-118.
MA28625A 2003-05-09 2005-11-24 Preparation et utilisation de derives d'aryl alkyl acide pour le traitement de l'obesite MA27843A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46961903P 2003-05-09 2003-05-09

Publications (1)

Publication Number Publication Date
MA27843A1 true MA27843A1 (fr) 2006-04-03

Family

ID=33452304

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28625A MA27843A1 (fr) 2003-05-09 2005-11-24 Preparation et utilisation de derives d'aryl alkyl acide pour le traitement de l'obesite

Country Status (24)

Country Link
US (5) US7091228B2 (fr)
EP (1) EP1633722B1 (fr)
JP (1) JP4759517B2 (fr)
KR (1) KR20060009916A (fr)
CN (1) CN1816531A (fr)
AR (1) AR044152A1 (fr)
AT (1) ATE518841T1 (fr)
AU (1) AU2004238258A1 (fr)
BR (1) BRPI0410170A (fr)
CA (1) CA2524470A1 (fr)
CL (1) CL2004000969A1 (fr)
EC (1) ECSP056210A (fr)
ES (1) ES2369220T3 (fr)
GT (1) GT200400092A (fr)
MA (1) MA27843A1 (fr)
MX (1) MXPA05012061A (fr)
NO (1) NO20055832L (fr)
NZ (1) NZ543993A (fr)
PE (1) PE20050265A1 (fr)
RU (1) RU2357959C2 (fr)
TW (1) TW200510334A (fr)
UY (1) UY28314A1 (fr)
WO (1) WO2004100881A2 (fr)
ZA (1) ZA200509883B (fr)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7759376B2 (en) * 2004-10-15 2010-07-20 Bayer Healthcare Llc Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity
AU2005315430B2 (en) * 2004-12-14 2010-05-27 Astrazeneca Ab Oxadiazole derivatives as DGAT inhibitors
WO2006082952A1 (fr) * 2005-02-01 2006-08-10 Takeda Pharmaceutical Company Limited Composé amide
JP2008529983A (ja) * 2005-02-07 2008-08-07 エフ．ホフマン−ラ ロシュ アーゲー ジアシルグリセロールアシルトランスフェラーゼ（ｄｇａｔ）の阻害剤
JP2008536947A (ja) * 2005-04-19 2008-09-11 バイエル・フアーマシユーチカルズ・コーポレーシヨン アリールアルキル酸誘導体およびそれらの使用
US20090215779A1 (en) * 2005-06-11 2009-08-27 Roger John Butlin Oxadiazole derivatives as dgat inhibitors
WO2007016538A2 (fr) * 2005-07-29 2007-02-08 Bayer Healthcare Llc Preparation et utilisation de derives aminoacides biphenyle pour traiter l'obesite
CN101296914B (zh) * 2005-08-26 2012-07-18 盐野义制药株式会社 具有ppar激动活性的衍生物
EP1963313B1 (fr) 2005-11-28 2012-11-14 Madrigal Pharmaceuticals, Inc. Inhibiteurs de diacylglycérol acyltransférase (dgat)
WO2007071966A1 (fr) 2005-12-22 2007-06-28 Astrazeneca Ab Pyrimido-[4,5-b]-oxazines pour utilisation en tant qu'inhibiteurs de dgat
EP2418202B1 (fr) 2006-03-31 2014-01-29 Novartis AG Dérivés (4-[4-[5-(substituted amino)-pyridin-2-yl]phenyl]-cyclohexyl)-acetic acid en tant qu'inhibiteurs de DGAT
US20080293785A1 (en) * 2006-04-11 2008-11-27 Connolly Peter J Substituted benzothiazole kinase inhibitors
US20070254952A1 (en) * 2006-04-21 2007-11-01 Yuguang Wang Cannabinoid receptor modulators
WO2007137107A2 (fr) * 2006-05-19 2007-11-29 Abbott Laboratories Inhibiteurs de l'enzyme diacylglycerol o-acyltransférase de type 1
US20080015227A1 (en) * 2006-05-19 2008-01-17 Kym Philip R Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
KR20090012349A (ko) * 2006-05-30 2009-02-03 아스트라제네카 아베 아세틸 조효소 ａ 디아실글리세롤 아실트랜스퍼라제의 억제제로서의 치환된 5-페닐아미노-1,3,4-옥사디아졸-2-일카르보닐아미노-4-페녹시-시클로헥산 카르복실산
AU2007266890B2 (en) 2006-05-30 2011-02-17 Astrazeneca Ab 1, 3, 4 -oxadiazole derivatives as DGAT1 inhibitors
CN101460469A (zh) * 2006-06-06 2009-06-17 阿斯利康(瑞典)有限公司 化合物
DE602007012875D1 (de) 2006-06-08 2011-04-14 Astrazeneca Ab Benzimidazole und ihre verwendung zur behandlung von diabetes
GB0611506D0 (en) * 2006-06-10 2006-07-19 Astrazeneca Ab Chemical compounds
GB0611552D0 (en) * 2006-06-12 2006-07-19 Astrazeneca Ab Chemical compounds
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
WO2008047694A1 (fr) * 2006-10-13 2008-04-24 Aska Pharmaceutical Co., Ltd. Procédé de fabrication d'un composé benzothiazole
CN101636155A (zh) 2006-11-29 2010-01-27 艾博特公司 二酰甘油o-酰基转移酶1型酶的抑制剂
US20080248115A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent
CA2685524A1 (fr) * 2007-04-30 2008-11-06 Abbott Laboratories Inhibiteurs d'enzyme diacylglycerol o-acyltransferase de type 1
JP2010526781A (ja) 2007-04-30 2010-08-05 アボット・ラボラトリーズ ジアシルグリセロールｏ−アシル転移酵素１型酵素の阻害剤
WO2008148840A1 (fr) 2007-06-08 2008-12-11 Janssen Pharmaceutica N.V. Dérivés de piperidine/piperazine
PA8783601A1 (es) 2007-06-08 2009-01-23 Janssen Pharmaceutica Nv Derivados de piperidina/piperazina
JO2972B1 (en) 2007-06-08 2016-03-15 جانسين فارماسوتيكا ان. في Piperidine / piperazine derivatives
WO2008148851A1 (fr) * 2007-06-08 2008-12-11 Janssen Pharmaceutica N.V. Dérivés de piperidine/piperazine
AR066169A1 (es) 2007-09-28 2009-07-29 Novartis Ag Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
CA2707660A1 (fr) 2007-12-20 2009-07-02 Astrazeneca Ab Composes carbamoyles comme inhibiteurs de dgat1 190
EP2242745A1 (fr) * 2008-02-07 2010-10-27 Sanofi-Aventis Nouvelles imidazolidines substituées par un phényle, procédé de production, médicaments contenant ces composés et leur utilisation
US8324241B2 (en) * 2008-04-11 2012-12-04 Bristol-Myers Squibb Company Triazolo compounds useful as DGAT1 inhibitors
WO2009126861A2 (fr) * 2008-04-11 2009-10-15 Bristol-Myers Squibb Company Composés de triazolopyridine utiles en tant qu'inhibiteurs de dgat1
PE20140572A1 (es) * 2008-06-05 2014-05-16 Janssen Pharmaceutica Nv Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
EP3025727A1 (fr) * 2008-10-02 2016-06-01 The J. David Gladstone Institutes Procédés de traitement des maladies du foie
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
US20110319396A1 (en) * 2009-01-23 2011-12-29 Msd K.K. Benzodiazepin-2-on derivatives
JP2012520886A (ja) 2009-03-18 2012-09-10 シェーリング コーポレイション ジアシルグリセロールアシルトランスフェラーゼの阻害剤としての二環式化合物
MX2011014018A (es) 2009-06-19 2012-02-22 Astrazeneca Ab Pirazincarboxamidas como inhibidores de dgati.
ES2443016T3 (es) 2009-08-26 2014-02-17 Sanofi Nuevos hidratos cristalinos de fluoroglicósidos heteroaromáticos, productos farmacéuticos que comprenden estos compuestos, y su empleo
WO2011031628A1 (fr) 2009-09-14 2011-03-17 Schering Corporation Inhibiteurs de diacylglycérol acyltransférase
US8722901B2 (en) 2009-11-05 2014-05-13 Piramal Enterprises Limited Carboxy oxazole or thiazole compounds as DGAT-1 inhibitors useful for the treatment of obesity
CN102905532A (zh) * 2010-02-09 2013-01-30 约翰斯.霍普金斯大学 用于改善认知功能的方法和组合物
AU2011235301B2 (en) 2010-03-30 2013-07-18 Novartis Ag Uses of DGAT1 inhibitors
WO2012064569A1 (fr) * 2010-11-08 2012-05-18 Merck Sharp & Dohme Corp. Dérivés d'imidazole
PH12013501268A1 (en) * 2010-12-17 2016-04-01 Mitsubishi Tanabe Pharma Corp Continuous arycyclic compound
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683705B1 (fr) 2011-03-08 2015-04-22 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
WO2012120050A1 (fr) 2011-03-08 2012-09-13 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, médicaments contenant ces composés et leur utilisation
EP2683701B1 (fr) 2011-03-08 2014-12-24 Sanofi Dérivés d'oxathiazine substitués par des groupes de benzyle-méthyles ou d'hétéro-méthyles, leur procédé de fabrication, leur utilisation comme médicament ainsi que médicaments en étant pourvu et leur utilisation
EP2683703B1 (fr) 2011-03-08 2015-05-27 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
EP2683704B1 (fr) 2011-03-08 2014-12-17 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
CN102757420B (zh) * 2011-04-28 2015-02-04 中国科学院上海药物研究所 联杂芳基羧酸类化合物、其制备方法,包含该化合物的药物组合物、及用途
KR20130013199A (ko) 2011-07-27 2013-02-06 한미약품 주식회사 신규 피리미딘 유도체 및 이를 활성성분으로 포함하는 약학 조성물
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
WO2013039140A1 (fr) * 2011-09-14 2013-03-21 第一三共株式会社 Dérivé hétérocyclique condensé
WO2013055910A1 (fr) 2011-10-12 2013-04-18 Arena Pharmaceuticals, Inc. Modulateurs du récepteur gpr119 et traitement de troubles associés
WO2013056679A1 (fr) * 2011-10-21 2013-04-25 Beijing Hanmi Pharmaceutical Co., Ltd Nouveaux dérivés amino-hétéroaryle
US9296745B2 (en) 2012-04-06 2016-03-29 Pfizer Inc. Diacylglycerol acyltransferase 2 inhibitors
JP5721032B2 (ja) * 2012-06-15 2015-05-20 田辺三菱製薬株式会社 医薬組成物
US9546155B2 (en) 2012-06-15 2017-01-17 Mitsubishi Tanabe Pharma Corporation Aromatic heterocyclic compound
WO2014074668A1 (fr) 2012-11-08 2014-05-15 Arena Pharmaceuticals, Inc. Modulateurs de gpr119 et traitement de troubles associés à ceux-ci
KR101772836B1 (ko) 2014-03-17 2017-08-29 화이자 인코포레이티드 대사 및 관련 장애의 치료에 사용하기 위한 디아실글리세롤 아실트랜스퍼라제 2 억제제
WO2018046428A1 (fr) * 2016-09-09 2018-03-15 F. Hoffmann-La Roche Ag Procédé de préparation de 2- (6-nitropyridin-3-yl) -9h-dipyrido [2,3-b; 3', 4'-d] pyrrole
EP3305786A3 (fr) 2018-01-22 2018-07-25 Bayer CropScience Aktiengesellschaft Dérivés d'hétérocyclène bicycliques condensés en tant que pesticides
KR102747096B1 (ko) 2018-03-16 2024-12-26 앤지 파마수티컬스 잉크. 심한 변비를 치료하기 위한 조성물 및 방법
WO2021066608A1 (fr) * 2019-10-02 2021-04-08 주식회사 클로소사이언스 Composé destiné à induire l'expression d'un gène klotho anti-âge et son utilisation
KR102863043B1 (ko) * 2020-01-29 2025-09-23 길리애드 사이언시즈, 인코포레이티드 Glp-1r 조절 화합물
WO2022109182A1 (fr) 2020-11-20 2022-05-27 Gilead Sciences, Inc. Composés modulateurs de glp-1r polyhétérocycliques
WO2023085931A1 (fr) 2021-11-11 2023-05-19 Koninklijke Nederlandse Akademie Van Wetenschappen Organoïdes hépatiques

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2112840A1 (de) 1971-03-17 1972-10-05 Thomae Gmbh Dr K Neue 4-(4-Biphenylyl)-buttersaeuren,ihre Salze und Ester
NL264710A (fr) * 1960-05-13
US3299087A (en) * 1961-04-24 1967-01-17 Geigy Chem Corp Nu, nu'-bis-(thiazolyl)-phenylenediamines
US3997589A (en) * 1971-03-17 1976-12-14 Boehringer Ingelheim Gmbh 4-(2'-Fluoro-4-biphenylylr-4-oxo-butyric acid and esters and salts thereof
DE2112716A1 (de) 1971-03-17 1972-10-05 Thomae Gmbh Dr K Neue 4-(4-Biphenylyl)-4-oxobuttersaeuren,ihre Salze und ihre Ester
DE2112715A1 (de) 1971-03-17 1972-10-05 Thomae Gmbh Dr K Neue 4-(4-Biphenylyl)-4-hydroxybuttersaeuren,ihre Salze,Ester und Lactone
US4021479A (en) * 1971-03-17 1977-05-03 Boehringer Ingelheim Gmbh Derivatives of 4-(4-biphenylyl)-butyric acid
DE3825617C2 (de) 1988-07-28 1993-11-18 W D Schumacher Einrichtung zur Entfernung von Schmutz oder anderen Verunreinigungen
US4948801A (en) 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
US5254577A (en) * 1988-07-29 1993-10-19 The Du Pont Merck Pharmaceutical Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
TW259786B (fr) * 1992-12-17 1995-10-11 Sankyo Co
GB2273930A (en) 1992-12-30 1994-07-06 Glaxo Group Ltd Benzanilide derivatives
GB2276162A (en) 1993-03-17 1994-09-21 Glaxo Group Ltd Aniline and benazilide derivatives
GB2276161A (en) 1993-03-17 1994-09-21 Glaxo Group Ltd Aniline and benzanilide derivatives
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
US5886022A (en) * 1995-06-05 1999-03-23 Bayer Corporation Substituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitors
TW429256B (en) * 1995-12-27 2001-04-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-(benzimidazolyl- and imidazopyridinyl)-piperidine derivatives
DE69939426D1 (de) 1998-06-24 2008-10-09 David Gladstone Inst Diacylglycerin o-acyltransferase
US6344548B1 (en) 1998-06-24 2002-02-05 The Regents Of The University Of California Diacylglycerol o-acyltransferase
DE69941390D1 (de) 1998-07-02 2009-10-22 Calgene Llc Diacylglyzerin-acyltransferase proteine
US6100077A (en) * 1998-10-01 2000-08-08 The Trustees Of Columbia University In The City Of New York Isolation of a gene encoding diacylglycerol acyltransferase
EP1031349A1 (fr) 1999-02-25 2000-08-30 Bayer Aktiengesellschaft Utilisation d'acides 4-biarylbutyriques et 5-biarylpentanoiques substitués pour traiter les maladies cérébrales
MXPA01012317A (es) * 2000-12-28 2002-07-22 Warner Lambert Co Prueba de aciltransferasa del diacilglicerol (dgat).

Also Published As

Publication number Publication date
EP1633722A2 (fr) 2006-03-15
CA2524470A1 (fr) 2004-11-25
US7968576B2 (en) 2011-06-28
US20090253762A1 (en) 2009-10-08
AR044152A1 (es) 2005-08-24
US20060194859A1 (en) 2006-08-31
US7091228B2 (en) 2006-08-15
ZA200509883B (en) 2007-03-28
US8013166B2 (en) 2011-09-06
MXPA05012061A (es) 2006-02-22
WO2004100881A2 (fr) 2004-11-25
CN1816531A (zh) 2006-08-09
ES2369220T3 (es) 2011-11-28
BRPI0410170A (pt) 2006-05-16
NZ543993A (en) 2009-06-26
WO2004100881A3 (fr) 2005-02-03
GT200400092A (es) 2005-01-11
UY28314A1 (es) 2004-11-30
EP1633722B1 (fr) 2011-08-03
PE20050265A1 (es) 2005-06-03
CL2004000969A1 (es) 2005-04-22
RU2005138134A (ru) 2006-06-27
TW200510334A (en) 2005-03-16
ECSP056210A (es) 2006-04-19
EP1633722A4 (fr) 2008-07-02
US20090270468A1 (en) 2009-10-29
US7423156B2 (en) 2008-09-09
ATE518841T1 (de) 2011-08-15
US20090197795A1 (en) 2009-08-06
JP4759517B2 (ja) 2011-08-31
NO20055832L (no) 2006-02-03
NO20055832D0 (no) 2005-12-08
KR20060009916A (ko) 2006-02-01
JP2007502862A (ja) 2007-02-15
US20040224997A1 (en) 2004-11-11
RU2357959C2 (ru) 2009-06-10
AU2004238258A1 (en) 2004-11-25

Similar Documents

Publication Publication Date Title
MA27843A1 (fr) Preparation et utilisation de derives d'aryl alkyl acide pour le traitement de l'obesite
Windeløv et al. Why is it so difficult to measure glucagon-like peptide-1 in a mouse?
Nedergaard et al. Type VI collagen turnover-related peptides—novel serological biomarkers of muscle mass and anabolic response to loading in young men
US20120083004A1 (en) Diagnostic Method for Celiac Sprue
Arciszewski et al. Vasoactive intestinal peptide rescues cultured rat myenteric neurons from lipopolysaccharide induced cell death
US20180318386A1 (en) Peptides and methods of treating endometriosis using the same
JP2004530640A (ja) Ｓｍｒ１ペプチドの新規な治療的使用
Bauer et al. Preferred stereoselective brain uptake of d-serine—a modulator of glutamatergic neurotransmission
Nandi et al. The absence of SIRT3 and SIRT5 promotes the acetylation of lens proteins and improves the chaperone activity of α-crystallin in mouse lenses
Maleszka et al. Expression of orexin A and B in the porcine hypothalamus during the oestrous cycle
CN1953988B (zh) 衍生自人bplp蛋白的肽、编码所述肽的多核苷酸和针对所述肽的抗体
Mikhrina et al. The role of AGRP in regulating dopaminergic neurons in the brain
Cakir-Kiefer et al. In vitro digestibility of α-casozepine, a benzodiazepine-like peptide from bovine casein, and biological activity of its main proteolytic fragment
Centeno et al. Lactoferricin-related peptides with inhibitory effects on ACE-dependent vasoconstriction
WO2003074549A3 (fr) Test d'anticorps anti-ingap
US20230013244A1 (en) Pif binding as a marker for immune dysregulation
Sadikali et al. Carnosinase activity of human gastrointestinal mucosa.
Astill et al. Promiscuous binding of proinsulin peptides to Type 1 diabetes-permissive and-protective HLA class II molecules
KR20150043343A (ko) 항체 및 카모스타트 메실레이트 (cm)를 포함하는 조성물
Roy et al. Development and validation of a simple, sensitive enzyme immunoassay (EIA) for quantification of prolactin in buffalo plasma
DE3789584T2 (de) Diagnose, Voraussage des Ausmasses und Kontrolle einer Erkrankung durch Immuntest von freien Aktivierungspeptiden von Pankreas-Zymogenen.
Iqbal Investigation of the effects of centrally injected nesfatin-1 on the hypothalamic cyclooxygenase and lipoxygenase enzymes using western blotting
Huneau et al. Histamine content, diamine oxydase and histidine decarboxylase activities along the intestinal tract of the rat
Anderson Biochemical biomarkers for autism spectrum disorder
Ohkawara et al. Macrophage migration inhibitory factor contributes to development of nonsteroidal anti-inflammatory drugs-induced gastric injury in mice